Research into cancer metabolomics: Towards a clinical metamorphosis. (July 2015)

• Record Type: Journal Article
• Authors: Olivares, Orianne; Däbritz, J. Henry M.; King, Ayala; Gottlieb, Eyal; Halsey, Christina
• Is Part Of: Seminars in cell & developmental biology. Volume 43(2015)
• Page Start: 52
• Page End: 64
• Publication Date: 2015-07
• Subjects: ACSS acetyl-CoA synthetase -- ADI arginine deiminase -- AML acute myeloid leukaemia -- AMPK AMP-activated protein kinase -- ALL acute lymphoblastic leukaemia -- ASS argininosuccinate synthase -- BCAAs branched-chain amino acids -- BPTES bis-2-(5-phenylacetamido-1, 3, 4-thiadiazol-2-yl)ethyl sulphide -- 2DG 2-deoxyglucose -- DHFR dihydrofolate reductase -- DMFO difluoromethylornithine -- FAS fatty acid synthase -- FDG 18-fluoro-deoxyglucose -- Fd-UMP 5-fluoro-2′-deoxyuridine monophosphate -- 18-F-FGln 4-18-F-(2S, 4R)-fluoro-glutamine -- FH fumarate hydratase -- FLT 18-fluoro-thymidine -- 5FU 5-fluorouracil -- F-UTP 5-fluorouridine triphosphate -- GIST gastrointestinal stromal tumours -- GLDC glycine decarboxylase -- GLS glutaminase -- 2HG 2-hydroxyglutarate -- HIF hypoxia-inducible factor -- IDH isocitrate dehydrogenase -- KD ketogenic diet -- LDH lactate dehydrogenase -- MCT monocarboxylate transporter -- MRI magnetic resonance imaging -- MRS magnetic resonance spectroscopy -- mTOR mammalian target of rapamycin -- NAD nicotinamide adenine dinucleotide -- NAMPT nicotinamide phosphoribosyltransferase -- NAPRT nicotinic acid phosphoribosyltransferase -- NMR nuclear magnetic resonance -- NSCLC non-small cell lung cancer -- PARP1 poly [ADP-ribose] polymerase 1 -- PC pyruvate carboxylase -- PDAC pancreatic ductal adenocarcinoma -- PET positron-emission tomography -- PHGDH D-3-phosphoglycerate dehydrogenase -- RCC renal cell carcinoma -- SDH succinate dehydrogenase -- SHMT serine hydroxyl-methyl-transferase -- SIRT1 silent information regulator 1 -- TCA tri-carboxylic acid -- THF tetrahydrofolate -- TK1 thymidine kinase 1; Biomarkers -- Cancer metabolism -- Cancer therapeutics -- Clinical trials -- Imaging; Cytology -- Periodicals; Developmental biology -- Periodicals; 571.6
• DOI: 10.1016/j.semcdb.2015.09.008
• Languages: English
• ISSNs: 1084-9521

Abstract

Highlights: Metabolism-related tools are employed to diagnose and treat cancer. Promising metabolic tracers and anti-cancer drugs are in clinical trials. Metabolomics provides new information on the vulnerabilities of malignant diseases. Abstract: The acknowledgement that metabolic reprogramming is a central feature of cancer has generated high expectations for major advances in both diagnosis and treatment of malignancies through addressing metabolism. These have so far only been partially fulfilled, with only a few clinical applications. However, numerous diagnostic and therapeutic compounds are currently being evaluated in either clinical trials or pre-clinical models and new discoveries of alterations in metabolic genes indicate future prognostic or other applicable relevance. Altogether, these metabolic approaches now stand alongside other available measures providing hopes for the prospects of metabolomics in the clinic. Here we present a comprehensive overview of both ongoing and emerging clinical, pre-clinical and technical strategies for exploiting unique tumour metabolic traits, highlighting the current promises and anticipations of research in the field.